Interestingly, Lovly and colleagues found that ensartinib exhibited a significantly higher IC50 value for the HepG2 cancer cell line as compared to other cell lines [2], which may be due, at least partially, to the activity of P-gp presented in the HepG2 cancer cells [73,74,75]. This evidence concerns the gene PGP and cancer.